Saxenda price in Spain: the real monthly cost and how it compares

Saxenda (liraglutide) is not funded by the Spanish National Health System, so the patient pays the full price. According to the Nomenclátor data reproduced by pharmaceutical reference sources, the pack of 5 pre-filled pens (national code 710663) has a retail price including VAT of €283.05 (ex-factory price €221.25) and the 3-pen pack costs €185.81 (ex-factory price €132.75). Because liraglutide is given daily, the monthly outlay does not match the price on the box: it depends on the dose you end up on.

What exactly you are buying when you pay €283.05

Saxenda comes in 3 ml pre-filled pens at a concentration of 6 mg of liraglutide per ml, that is, 18 mg per pen. The EMA authorised packs of 1, 3 and 5 pens (marketing authorisation numbers EU/1/15/992/001-003), although not every presentation has to be marketed in every country. In Spain, the codes listed with a price are the 5-pen and the 3-pen packs.

That figure of 18 mg per pen is what lets you convert price into days of treatment, and it is worth doing the sums sooner rather than later. The summary of product characteristics describes a weekly escalation: 0.6 mg a day in the first week, 1.2 mg in the second, 1.8 mg in the third, 2.4 mg in the fourth and 3.0 mg a day from the fifth week onwards. At the maintenance dose of 3 mg daily, the 18 mg in a pen lasts six days. Early in treatment, on low doses, the same pen goes much further.

Two limits constrain that arithmetic and are often overlooked. The first is in-use shelf life: the unopened product has a shelf life of 30 months, but once the pen has been used for the first time it must be used within one month. The second is storage: pens that have not been started are kept in the fridge at 2 to 8 °C and must not be frozen. This is not, therefore, a product you can stockpile to stretch a pack indefinitely.

Why it is not funded and what that means for the bill

In Spanish dispensing records, Saxenda is listed as not reimbursable by the National Health System, and that applies to all its indications. The practical consequence is simple: there is no reduced contribution or co-payment, you pay the full retail price at the pharmacy. Whether the prescription comes from an endocrinologist, from primary care or from a private consultation makes no difference, because the decision to fund or not is an administrative one and applies to the medicine, not to the prescriber.

Saxenda is not alone in this. Wegovy (semaglutide for weight management) is also listed as not funded by resolution in BIFIMED, the Spanish Ministry of Health's pharmaceutical benefit database. In the case of Ozempic, semaglutide at doses of up to 1 mg is funded only for type 2 diabetes and subject to prior authorisation, which does not cover use for weight management. If you want the detail on that medicine, we cover it in the guide to Ozempic in Spain and who can take it and in the updated breakdown of its price per pen and per month.

The mistake of comparing pack prices

Looking only at the label on the box leads to false conclusions, because the regimens are not equivalent. Saxenda is given daily; Wegovy and Mounjaro, weekly. A Wegovy pen of 0.25, 0.5 or 1 mg costs €179.89 and covers four weekly injections; the 1.7 mg pen, €200.19; the 2.4 mg pen, €223.64. With Mounjaro, the KwikPen ranges from €207.91 (2.5 mg) to €446.07 (12.5 and 15 mg), and each pen likewise equates to four weekly doses. To compare properly you have to put everything in the same unit: what a month of treatment costs at the dose actually being used.

The reason liraglutide is injected daily is pharmacokinetic, not commercial. Its absolute bioavailability by the subcutaneous route is around 55%, maximum concentration is reached at about 11 hours and absorption is slow, a profile that requires daily dosing. The more recent analogues are designed for a much longer half-life, hence the weekly regimen. If you are interested in the other end of the comparison, you can see how much Mounjaro costs per month in Spain or the price of Rybelsus, oral semaglutide.

Needles are not included in the price either, as they are bought separately. It is a minor expense, but it is real, and worth counting when working out the monthly budget.

What the evidence says about cost per result

There is one figure that changes how you read any price comparison. In the STEP 8 trial, published in JAMA in 2022, semaglutide 2.4 mg weekly produced a mean weight change of -15.8% compared with -6.4% for liraglutide 3.0 mg daily, with -1.9% in the placebo group. The difference between the two drugs was 9.4 percentage points (95% CI -12.0 to -6.8; p<0.001). At clinically relevant thresholds the gap is even more striking: 70.9% of participants on semaglutide achieved a loss of at least 10%, compared with 25.6% on liraglutide (OR 6.3), and 55.6% versus 12.0% for a loss of at least 15% (OR 7.9).

Using those data, a cost-effectiveness analysis carried out in Greece calculated the cost for each patient achieving a weight loss of at least 10%: €4,631.43 with semaglutide versus €10,695.63 with liraglutide. These are prices from the Greek system and cannot be transferred to Spain, but the methodological message does travel: the medicine with the more affordable box can turn out to be the most expensive per result obtained. That is the useful question, not which one costs less over the counter.

As for cardiovascular safety, the Saxenda summary of product characteristics records 6 major adverse cardiovascular events with liraglutide versus 10 with placebo in long-term trials (HR 0.33; 95% CI 0.12-0.90). These numbers are far too small to conclude that there is a demonstrated cardiovascular benefit with this indication, and the documentation itself presents them as descriptive data, not as a claim of efficacy.

Who it is authorised for, and why that also affects the price

The authorised indication for Saxenda is weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity, always alongside diet and exercise. Put another way: it is not a product for shifting the last few kilos, but a medicine with prescribing criteria, prescription-only dispensing and follow-up. That initial assessment is what determines whether it makes sense in a particular case and at what dose, and it is also what stops you spending money on a treatment that does not fit.

The population context explains the demand. According to the ENE-COVID study by the ISCIII and AESAN, which analysed 57,131 adults and 10,543 children, 55.8% of adults in Spain are above a healthy weight and 18.7% have obesity, with 4.9% having severe obesity; among children, a third are above a healthy weight and one in ten has obesity. The INE's 2023 Spanish Health Survey puts the highest rates of adult obesity in the Canary Islands (20.6%), the Region of Murcia (20.1%) and Castilla-La Mancha (19.9%). Behind many of those cases lie metabolic changes worth understanding: you can read how they are managed in the guide to insulin resistance and how to reverse it.

What to take away and where to go next

The price of Saxenda in Spain is well known and it is not funded: €283.05 for the 5-pen pack and €185.81 for the 3-pen pack, with daily dosing and a monthly cost that rises once you reach 3 mg. But the number that really matters is the cost per result, and there liraglutide has fallen behind more recent alternatives in head-to-head comparisons. Deciding that is not a matter of browsing a catalogue, but of a clinical assessment of your case. At AiON we offer medical weight loss treatment with an initial assessment, a prescription from a registered doctor where appropriate and ongoing follow-up. You can check in a few minutes whether the treatment fits your case.